Login to Your Account



Other News To Note


Friday, February 1, 2013
• Dyax Corp., of Burlington, Mass., and Novellus Biopharma AG, of Bogota, Colombia, inked a partnership for the development and commercialization of hereditary angioedema drug Kalbitor (ecallantide) in select regions in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico and Venezuela.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription